Featured Clinical Trials

Mary Fox, Vice President, [email protected]

The goal of this research is to understand the diagnosis and treatment journey for people living with stage 1 or 2 non-small cell lung cancer, to better engage with and meet the needs of earlier-stage patients whose tumors cannot be removed by surgery. By understanding the real-life stories and experiences of patients and their family caregivers, a company that makes FDA-approved treatments for early-stage NSCLC will be able to offer better information and support to these patients, their family caregivers, and even their medical treatment teams.

You can participate if you:

1. Have been diagnosed within the last 7 years; and
2. Cannot have (or do not want) surgery to treat your lung cancer

We would also love to talk to some family caregivers to understand the support perspective as well!

We are looking primarily for patients who are 50+ years old, although we can accept a few younger folks too.

Please apply here: https://sommer.iad1.qualtrics.com/jfe/form/SV_3KrcKv42yScsJRY

Dr. Paul Romesser and Dr. Matthew McMillan
Contact Number: 646-888-2118

Immunotherapy with or without chemotherapy is the standard treatment for newly diagnosed metastatic non-small cell lung cancer (NSCLC), but it is much less effective for metastatic NSCLC patients with cancer that has spread to their liver. Prior work has shown that treating cancer that has spread to the liver with high-dose radiotherapy (i.e., L-SABR) might make immunotherapy more effective.

Therefore, in this study, patients with newly diagnosed metastatic NSCLC that has spread to the liver (and no known targetable EGFR, ALK, BRAF, or ROS1 alterations) will be randomly assigned to receive L-SABR in addition to their standard immunotherapy (with or without chemotherapy) or continue to receive standard immunotherapy (with or without chemotherapy) alone. Notably, if assigned to the L-SABR group, L-SABR must be completed prior to the third cycle of immunotherapy or within 90 days of the first immunotherapy treatment.

You are eligible to participate if:

1. You are newly diagnosed with metastatic non-small cell lung cancer (NSCLC) – nonsquamous NSCLC, squamous cell lung cancer, or large cell lung cancer
2. Your tumor has no known biomarkers (EGFR, ALK, BRAF, or ROS1 alterations)

[email protected]

ALISCA-Lung1 is a clinical trial that is exploring whether an investigational medication called alisertib is effective in treating patients with pathologically confirmed small cell lung cancer following progression on or after treatment with one platinum-based chemotherapy and an anti-PD-L1 immunotherapy agent. Up to one additional systemic anti-cancer therapy for SCLC is allowed, for a total of up to two prior lines of therapy.

Who can participate?

The study is open for the following types of lung cancer:

• Small cell lung cancer

Eligible patients must be at least 18 years old and cannot have used an AURKA specific-targeted or pan-Aurora-targeted agent, including alisertib, in any setting. There are additional inclusion and exclusion criteria. The investigator at the study center will determine if you meet all of the criteria.